A5048553572- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Sarcoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Lung Cancer Research Studies
- Chromatin Remodeling and Cancer
- Lung Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Chronic Myeloid Leukemia Treatments
- Economic and Financial Impacts of Cancer
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Multiple and Secondary Primary Cancers
- Head and Neck Cancer Studies
- Vascular Tumors and Angiosarcomas
- Chemotherapy-induced cardiotoxicity and mitigation
- Protein Degradation and Inhibitors
- Biosimilars and Bioanalytical Methods
- Lymphoma Diagnosis and Treatment
Christian Medical College & Hospital
2021-2025
Christian Medical College
2021-2024
Jawaharlal Institute of Post Graduate Medical Education and Research
2020-2022
PURPOSE There is a lack of literature on treating stage III non–oncogene-driven non–small cell lung cancer (NSCLC) with low-dose immunotherapy in combination chemotherapy for patients who are not candidates local therapy up front. MATERIALS AND METHODS We performed an institutional retrospective analysis NSCLC deemed ineligible up-front therapy. The NACT + I/O group comprised those received induction nivolumab, and the NACT-alone alone. Propensity score matching was based stage, histology,...
Background: To determine if circulating tumor DNA (ct-DNA) dynamics of epidermal growth factor receptor (EGFR) mutation in plasma can identify a subset patients with EGFR-mutant (EGFR-m) non-small cell lung cancer (NSCLC) inferior survival outcomes, we analyzed and compared outcomes among without baseline presence early clearance EGFR ct-DNA plasma.Material methods: For 66 newly dia gnosed EGFR-m NSCLC, samples were collected at 1 st response assessment 12-24 weeks for extraction...
Pseudomyogenic hemangioendothelioma (PMHE), a rare soft tissue tumor predominantly affecting young adults, often presents as multiple nodules in various planes of limb. Malignant transformation and metastatic disease are unusual pose diagnostic therapeutic challenges. A 17-year-old patient from Western India, with history recurrent excisions for toe swelling presented to our center evaluation management. below-knee amputation was performed, histopathology revealed PMHE. Adjuvant therapy...
Response to neoadjuvant chemotherapy is associated with improved outcomes for patients triple negative breast cancer (TNBC). Patients residual disease are at increased risk of relapse and death from cancer. In this retrospective study, we aimed evaluate the efficacy safety cisplatin added standard locally advanced TNBC.All TNBC treated 60mg/m2 once in 3 weeks weekly paclitaxel 12 weeks, following 8 dose-dense epirubicin 90mg/m2 or doxorubicin cyclophosphamide 600mg/m2 were analyzed...
e16544 Background: Nivolumab with cabozantinib is an accepted treatment option for metastatic RCC (mRCC). Generic TKI access has improved, although nivolumab at currently licensed doses remains unaffordable in India. Immunotherapy not reimbursable through national health insurance schemes, therefore patients pay out-of-pocket. We evaluated the practice patterns and clinical outcomes low dose combined a tertiary academic hospital Methods: reviewed abstracted records of mRCC treated TKIs...
Primary mucosal melanomas are rare and aggressive malignancies with limited available information as they excluded from melanoma trials. They unique exhibit a different molecular profile mutational burden, when compared to cutaneous melanoma. Activity of commonly used regimens is not well defined, therefore, there no consensus on the optimal first-line treatment. The study was conducted at Christian Medical College, Vellore, India, between January 01, 2012, 2022. hospital system retrieve...
We assessed the efficacy, tolerability, and cost-effectiveness of a novel neoadjuvant regimen comprising docetaxel-cyclophosphamide alternating with epirubicin-cisplatin (ddDCEP) administered biweekly for 16 weeks in 116 patients early triple-negative breast cancer. This achieved high pathological complete response (ypT0/TisN0) rate 55.2% favorable survival outcomes (30-month event-free survival, 91.2%; overall 97%). Febrile neutropenia was observed 4.3% patients, 98% completed at least six...
Background: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with poor prognosis and access to anti-HER2 treatment still a challenge in lower-middle income countries.The availability of the biosimilar trastuzumab has improved by lowering costs.We report pattern use neoadjuvant ± adjuvant outcomes patients HER2-positive non-metastatic treated regimens incorporating shorter durations therapy compared innovator. Methods:We conducted retrospective analysis...
Adjuvant chemotherapy after surgery for gastric cancer improves survival but is difficult to administer due poor tolerance. Combination with Docetaxel (Taxotere), Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) (TEX) used in the treatment of advanced cancer. The efficacy tolerability this regimen post resection have not been studied.Patients diagnosed adenocarcinoma, without any prior between July 2007 May 2011 treated TEX administered as T 35 mg/m2 E 50 on days (d) 1, 8 X 625 bid (twice...
Abstract Purpose The addition of carboplatin has improved pathological complete response (PCR) and event-free survival (EFS) is becoming a new standard care for early triple-negative breast cancer (TNBC). However, this comes at the expense increased toxicity. Here, we aimed to evaluate novel cisplatin-based chemotherapy regimen TNBC. Methods Women with TNBC who were administered neoadjuvant consisting four cycles docetaxel cyclophosphamide alternated cisplatin epirubicin (ddDCEP) given every...
Abstract We assessed the efficacy, tolerability, and cost-effectiveness of a novel neoadjuvant regimen comprising docetaxel-cyclophosphamide alternating with epirubicin-cisplatin (ddDCEP) administered biweekly for 16 weeks in 116 patients early triple-negative breast cancer. This achieved high pathological complete response (ypT0/TisN0) rate 55.2% favorable survival outcomes (30-month event-free survival, 91.2%; overall 97%). Febrile neutropenia was observed 4.3% patients, 98% completed at...
Abstract Aim Triple negative subtype (TNBC) is an aggressive breast cancer with inferior survival. Pathological CR (pCR) a good surrogate endpoint for survival among patients receiving neoadjuvant chemotherapy (NACT). We attempted to validate the composite score(CPS) (Jaccqueline et al, J Clin Oncol 26:246-252) combining clinical and pathological variables TNBC NACT at our center. Methodology Data of who underwent between January 2014 July 2017 was retrospectively analysed. The CPS score...
Abstract Purpose Carboplatin-containing treatment regimens in early TNBC have shown improved pCR(pathological complete response) and better EFS(event-free survival) but at the expense of increased toxicity, often leading to compromised delivery planned treatment. We aimed evaluate a novel alternating regimen incorporate platinum TNBC. Methods analyzed data women with who were treated four cycles each docetaxel(D;75 mg/m2) cyclophosphamide(C;600 cisplatin(P;60 epirubicin(E;90 (ddDCEP) given...
Abstract Background: Patients with platinum-resistant ovarian cancer (PROC) have limited therapeutic options and poor survival. There is a need for the development of newer therapies. Sodium valproic acid (VPA) short-chain fatty histone deacetylase (HDAC) inhibitor antitumor activity in preclinical models PROC. Synergism conventional cytotoxic agents like etoposide has been demonstrated. Methodology: In this prospective, single-arm, open-label, phase 2 study, we included patients ≥18 years...
Abstract Purpose In a developing country like India, genomic data sets for even the most clinically relevant genes BRCA1 and BRCA2 is rather scarce. Also, there need to identify screen population specific BRCA hotspots pave way affordable genetic testing strategies in clinical practice. Method This an ambispective study evaluate NGS based approach pathogenic variants among 430 patients with Breast Ovarian cancers. The target enrichment was carried out using in-house designed Multiplex-PCR...